Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 53 | 2024 | 5666 | 1.730 |
Why?
|
Transplantation Conditioning | 37 | 2023 | 1591 | 1.480 |
Why?
|
Graft vs Host Disease | 25 | 2024 | 3025 | 0.810 |
Why?
|
Leukemia, Myeloid, Acute | 16 | 2023 | 3610 | 0.750 |
Why?
|
Bone Marrow Transplantation | 19 | 2020 | 2692 | 0.670 |
Why?
|
Cord Blood Stem Cell Transplantation | 8 | 2019 | 305 | 0.660 |
Why?
|
Hematologic Neoplasms | 19 | 2019 | 1895 | 0.640 |
Why?
|
Busulfan | 8 | 2015 | 258 | 0.480 |
Why?
|
Transplantation, Homologous | 22 | 2019 | 4822 | 0.450 |
Why?
|
Lymphoma, Non-Hodgkin | 7 | 2014 | 1372 | 0.410 |
Why?
|
Myeloablative Agonists | 4 | 2014 | 209 | 0.370 |
Why?
|
Transplantation Chimera | 12 | 2019 | 594 | 0.370 |
Why?
|
Hematologic Diseases | 3 | 2023 | 496 | 0.370 |
Why?
|
Lymphoma | 7 | 2022 | 1898 | 0.360 |
Why?
|
fms-Like Tyrosine Kinase 3 | 4 | 2016 | 496 | 0.360 |
Why?
|
Cyclophosphamide | 15 | 2023 | 2219 | 0.350 |
Why?
|
Transplantation, Autologous | 19 | 2017 | 2112 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 18 | 2022 | 11733 | 0.340 |
Why?
|
Stem Cell Transplantation | 7 | 2015 | 1600 | 0.340 |
Why?
|
Niacinamide | 3 | 2016 | 413 | 0.310 |
Why?
|
Phenylurea Compounds | 3 | 2016 | 529 | 0.290 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 1549 | 0.270 |
Why?
|
Immunoconjugates | 3 | 2019 | 963 | 0.270 |
Why?
|
Histocompatibility Testing | 8 | 2019 | 716 | 0.260 |
Why?
|
Myeloproliferative Disorders | 2 | 2022 | 609 | 0.250 |
Why?
|
Vidarabine | 5 | 2019 | 336 | 0.240 |
Why?
|
Kidney Failure, Chronic | 6 | 2019 | 2478 | 0.240 |
Why?
|
Central Nervous System Neoplasms | 3 | 2022 | 915 | 0.230 |
Why?
|
Whole-Body Irradiation | 2 | 2019 | 432 | 0.230 |
Why?
|
Kidney Transplantation | 6 | 2019 | 4242 | 0.200 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1468 | 0.190 |
Why?
|
Antigens, CD19 | 2 | 2022 | 424 | 0.180 |
Why?
|
Primary Myelofibrosis | 1 | 2023 | 208 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.170 |
Why?
|
Blast Crisis | 1 | 2020 | 102 | 0.170 |
Why?
|
Hodgkin Disease | 2 | 2011 | 1379 | 0.170 |
Why?
|
Heart Murmurs | 1 | 2020 | 92 | 0.170 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2013 | 263 | 0.170 |
Why?
|
Disease-Free Survival | 15 | 2019 | 6819 | 0.170 |
Why?
|
Myelodysplastic Syndromes | 3 | 2015 | 1393 | 0.170 |
Why?
|
Sarcoma, Myeloid | 1 | 2020 | 52 | 0.170 |
Why?
|
Middle Aged | 70 | 2024 | 220858 | 0.170 |
Why?
|
Granulocyte Colony-Stimulating Factor | 5 | 2007 | 629 | 0.160 |
Why?
|
Aged | 52 | 2024 | 169292 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 466 | 0.160 |
Why?
|
Hematopoietic Stem Cell Mobilization | 4 | 2007 | 225 | 0.160 |
Why?
|
Antifungal Agents | 2 | 2020 | 752 | 0.150 |
Why?
|
Fetal Blood | 3 | 2016 | 1348 | 0.150 |
Why?
|
Tandem Repeat Sequences | 2 | 2016 | 180 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 301 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 328 | 0.150 |
Why?
|
Adult | 59 | 2024 | 221120 | 0.140 |
Why?
|
Cytarabine | 5 | 2019 | 697 | 0.140 |
Why?
|
HLA Antigens | 4 | 2019 | 1331 | 0.140 |
Why?
|
Lymphocyte Transfusion | 3 | 2008 | 232 | 0.130 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 333 | 0.130 |
Why?
|
Heart Neoplasms | 1 | 2020 | 364 | 0.130 |
Why?
|
Histocompatibility | 3 | 2009 | 319 | 0.130 |
Why?
|
Melphalan | 3 | 2019 | 420 | 0.130 |
Why?
|
Humans | 101 | 2024 | 761222 | 0.130 |
Why?
|
Bacteremia | 2 | 2020 | 978 | 0.130 |
Why?
|
Graft vs Tumor Effect | 2 | 2008 | 68 | 0.130 |
Why?
|
Male | 64 | 2024 | 360703 | 0.130 |
Why?
|
Remission Induction | 7 | 2022 | 2392 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2022 | 1605 | 0.130 |
Why?
|
Arabinonucleosides | 1 | 2015 | 34 | 0.130 |
Why?
|
Eosinophilia | 1 | 2020 | 557 | 0.130 |
Why?
|
Etoposide | 2 | 2019 | 635 | 0.130 |
Why?
|
Adenine Nucleotides | 1 | 2015 | 110 | 0.130 |
Why?
|
Multiple Myeloma | 6 | 2019 | 5145 | 0.120 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 686 | 0.120 |
Why?
|
Female | 69 | 2024 | 392552 | 0.120 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
Combined Modality Therapy | 13 | 2018 | 8519 | 0.120 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2018 | 360 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2022 | 2549 | 0.120 |
Why?
|
Bone Marrow | 3 | 2020 | 2911 | 0.110 |
Why?
|
Urate Oxidase | 1 | 2014 | 31 | 0.110 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 694 | 0.110 |
Why?
|
Graft Survival | 8 | 2019 | 3843 | 0.110 |
Why?
|
Parathyroid Hormone | 2 | 2012 | 1803 | 0.110 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2014 | 418 | 0.110 |
Why?
|
Quality of Life | 5 | 2018 | 13367 | 0.100 |
Why?
|
Antineoplastic Agents | 7 | 2016 | 13632 | 0.100 |
Why?
|
Maximum Tolerated Dose | 4 | 2019 | 883 | 0.100 |
Why?
|
Integrin alpha4 | 1 | 2012 | 87 | 0.100 |
Why?
|
Immune Tolerance | 5 | 2019 | 2307 | 0.100 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1232 | 0.100 |
Why?
|
Integrin beta Chains | 1 | 2012 | 115 | 0.100 |
Why?
|
Carmustine | 1 | 2012 | 137 | 0.100 |
Why?
|
Palliative Care | 2 | 2017 | 3599 | 0.100 |
Why?
|
Respirovirus Infections | 1 | 2011 | 51 | 0.100 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 657 | 0.100 |
Why?
|
Sirolimus | 2 | 2016 | 1540 | 0.100 |
Why?
|
Treatment Outcome | 23 | 2024 | 64681 | 0.090 |
Why?
|
Leukocytosis | 1 | 2012 | 251 | 0.090 |
Why?
|
Survival Analysis | 11 | 2018 | 10088 | 0.090 |
Why?
|
Pyrimidines | 2 | 2021 | 3027 | 0.090 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 382 | 0.090 |
Why?
|
Recurrence | 5 | 2023 | 8457 | 0.090 |
Why?
|
Affect | 2 | 2015 | 1486 | 0.090 |
Why?
|
Health Resources | 1 | 2016 | 934 | 0.090 |
Why?
|
Pilot Projects | 5 | 2024 | 8642 | 0.090 |
Why?
|
Retrospective Studies | 24 | 2024 | 80675 | 0.090 |
Why?
|
Mycoses | 1 | 2013 | 386 | 0.090 |
Why?
|
Chromosome Deletion | 1 | 2014 | 1386 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2017 | 4574 | 0.080 |
Why?
|
Survival Rate | 9 | 2015 | 12728 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5665 | 0.080 |
Why?
|
Young Adult | 17 | 2020 | 59222 | 0.080 |
Why?
|
Acute Disease | 5 | 2024 | 7226 | 0.080 |
Why?
|
Thymus Gland | 3 | 2010 | 1243 | 0.080 |
Why?
|
Virus Activation | 1 | 2010 | 319 | 0.080 |
Why?
|
Intestinal Diseases | 1 | 2012 | 503 | 0.070 |
Why?
|
Drug Administration Schedule | 5 | 2019 | 4851 | 0.070 |
Why?
|
Carcinoma | 1 | 1999 | 2330 | 0.070 |
Why?
|
Hepatitis B virus | 1 | 2010 | 527 | 0.070 |
Why?
|
Viremia | 1 | 2010 | 707 | 0.070 |
Why?
|
Caregivers | 2 | 2016 | 2244 | 0.070 |
Why?
|
Hepatitis B, Chronic | 1 | 2010 | 410 | 0.060 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2023 | 937 | 0.060 |
Why?
|
Immunologic Memory | 1 | 2012 | 1361 | 0.060 |
Why?
|
Carboplatin | 4 | 2002 | 793 | 0.060 |
Why?
|
Ovarian Neoplasms | 2 | 2001 | 4872 | 0.060 |
Why?
|
Idarubicin | 2 | 2019 | 59 | 0.060 |
Why?
|
Cytomegalovirus | 1 | 2010 | 750 | 0.060 |
Why?
|
Antibodies, Monoclonal | 4 | 2010 | 9187 | 0.060 |
Why?
|
Interleukin-2 | 2 | 2003 | 1891 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2013 | 9278 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 2 | 2011 | 3726 | 0.060 |
Why?
|
Vincristine | 2 | 2022 | 1036 | 0.060 |
Why?
|
Immunosuppressive Agents | 5 | 2019 | 4190 | 0.050 |
Why?
|
Thiotepa | 2 | 2014 | 66 | 0.050 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2009 | 220 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 2010 | 828 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 1996 | 3390 | 0.050 |
Why?
|
Amyloidosis | 1 | 2010 | 865 | 0.050 |
Why?
|
Stress, Psychological | 1 | 2018 | 4487 | 0.050 |
Why?
|
Lymphopoiesis | 1 | 2002 | 133 | 0.050 |
Why?
|
Tacrolimus | 2 | 2016 | 736 | 0.050 |
Why?
|
Salvage Therapy | 3 | 2009 | 1264 | 0.050 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2022 | 163 | 0.050 |
Why?
|
Massachusetts | 3 | 2021 | 8837 | 0.040 |
Why?
|
Boron Compounds | 1 | 2022 | 182 | 0.040 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39127 | 0.040 |
Why?
|
Ohio | 1 | 2021 | 322 | 0.040 |
Why?
|
Incidence | 4 | 2023 | 21366 | 0.040 |
Why?
|
Graft Rejection | 5 | 2006 | 4481 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 1405 | 0.040 |
Why?
|
Pneumonia | 1 | 2012 | 2142 | 0.040 |
Why?
|
Pneumocystis | 1 | 1999 | 55 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2019 | 148 | 0.040 |
Why?
|
Lymphocytes | 2 | 2010 | 2603 | 0.040 |
Why?
|
Depression | 3 | 2016 | 8132 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2022 | 2509 | 0.040 |
Why?
|
Naphthoquinones | 1 | 1999 | 58 | 0.040 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2017 | 4575 | 0.040 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2001 | 258 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2017 | 3092 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2018 | 5250 | 0.040 |
Why?
|
Adolescent | 15 | 2017 | 88300 | 0.040 |
Why?
|
Tissue Donors | 3 | 2010 | 2335 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2011 | 3048 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5333 | 0.040 |
Why?
|
Methotrexate | 2 | 2016 | 1718 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2014 | 4021 | 0.040 |
Why?
|
Glycine | 1 | 2022 | 659 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 312 | 0.040 |
Why?
|
Neoplasms | 4 | 2020 | 22142 | 0.040 |
Why?
|
Arthritis, Gouty | 1 | 1998 | 28 | 0.040 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1999 | 242 | 0.040 |
Why?
|
Leukocyte Transfusion | 3 | 2003 | 56 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 373 | 0.040 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1791 | 0.040 |
Why?
|
Parent-Child Relations | 1 | 2002 | 762 | 0.030 |
Why?
|
Heart Transplantation | 1 | 2010 | 3258 | 0.030 |
Why?
|
Living Donors | 2 | 1999 | 643 | 0.030 |
Why?
|
Spleen | 1 | 2023 | 2290 | 0.030 |
Why?
|
Boronic Acids | 2 | 2013 | 915 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 971 | 0.030 |
Why?
|
Lung | 1 | 2014 | 9979 | 0.030 |
Why?
|
Leukapheresis | 1 | 1996 | 134 | 0.030 |
Why?
|
Inpatients | 2 | 2017 | 2545 | 0.030 |
Why?
|
Body Mass Index | 1 | 2013 | 12952 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 637 | 0.030 |
Why?
|
Pyrazines | 2 | 2013 | 1202 | 0.030 |
Why?
|
Hospitals, University | 1 | 2016 | 565 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 1999 | 858 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5809 | 0.030 |
Why?
|
Bangladesh | 1 | 2016 | 732 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 11855 | 0.030 |
Why?
|
Dermatitis, Exfoliative | 1 | 2014 | 27 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2003 | 2194 | 0.030 |
Why?
|
Risk Factors | 6 | 2019 | 74241 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6504 | 0.030 |
Why?
|
Cytogenetic Analysis | 1 | 2014 | 270 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2016 | 422 | 0.030 |
Why?
|
Hospitalization | 4 | 2017 | 10707 | 0.030 |
Why?
|
Survivors | 1 | 2024 | 2369 | 0.030 |
Why?
|
Age Factors | 3 | 2015 | 18384 | 0.030 |
Why?
|
Mass Screening | 2 | 2024 | 5426 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1662 | 0.030 |
Why?
|
Family | 2 | 2007 | 3192 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 890 | 0.020 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2011 | 25 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2018 | 834 | 0.020 |
Why?
|
Antilymphocyte Serum | 2 | 2007 | 491 | 0.020 |
Why?
|
Mutation | 2 | 2014 | 30004 | 0.020 |
Why?
|
Cryopreservation | 1 | 2016 | 728 | 0.020 |
Why?
|
Flow Cytometry | 3 | 2012 | 5871 | 0.020 |
Why?
|
Pulmonary Edema | 1 | 2014 | 408 | 0.020 |
Why?
|
Cell Separation | 1 | 2016 | 1721 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2012 | 252 | 0.020 |
Why?
|
Aftercare | 1 | 2017 | 913 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 2010 | 0.020 |
Why?
|
Hepatitis Antibodies | 1 | 2010 | 67 | 0.020 |
Why?
|
Neutrophils | 2 | 2016 | 3763 | 0.020 |
Why?
|
Cough | 1 | 2014 | 594 | 0.020 |
Why?
|
Mediastinum | 1 | 2012 | 267 | 0.020 |
Why?
|
Interferon-gamma | 2 | 2010 | 3155 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2217 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2507 | 0.020 |
Why?
|
Fatigue | 1 | 2016 | 1550 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2013 | 646 | 0.020 |
Why?
|
Attitude to Health | 1 | 1998 | 2026 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2010 | 411 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 651 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2012 | 4373 | 0.020 |
Why?
|
Nasopharynx | 1 | 2011 | 400 | 0.020 |
Why?
|
T-Lymphocytes | 4 | 2014 | 10203 | 0.020 |
Why?
|
Prognosis | 3 | 2015 | 29688 | 0.020 |
Why?
|
Serologic Tests | 1 | 2010 | 381 | 0.020 |
Why?
|
Administration, Inhalation | 1 | 2011 | 1159 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2018 | 2189 | 0.020 |
Why?
|
Alanine | 1 | 2010 | 608 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5301 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 885 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2317 | 0.020 |
Why?
|
Uric Acid | 1 | 2014 | 807 | 0.020 |
Why?
|
Macrocyclic Compounds | 1 | 2007 | 68 | 0.020 |
Why?
|
Syndrome | 1 | 2014 | 3271 | 0.020 |
Why?
|
Time Factors | 6 | 2008 | 39957 | 0.020 |
Why?
|
Receptors, Complement 3b | 1 | 2007 | 136 | 0.020 |
Why?
|
Cardiotonic Agents | 1 | 2010 | 540 | 0.020 |
Why?
|
Chest Pain | 1 | 2014 | 1097 | 0.020 |
Why?
|
Erythroblasts | 1 | 2007 | 142 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2413 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 6011 | 0.020 |
Why?
|
Filgrastim | 1 | 2007 | 132 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2017 | 1663 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2009 | 537 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2011 | 1685 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2020 | 58952 | 0.020 |
Why?
|
Dyspnea | 1 | 2014 | 1347 | 0.020 |
Why?
|
Fever | 1 | 2014 | 1618 | 0.020 |
Why?
|
Heart Failure | 1 | 2010 | 11701 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4642 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2011 | 858 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2012 | 10756 | 0.020 |
Why?
|
Mycophenolic Acid | 1 | 2007 | 350 | 0.020 |
Why?
|
Patient Care Team | 1 | 2016 | 2515 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2018 | 3453 | 0.020 |
Why?
|
Prednisone | 1 | 2010 | 1565 | 0.020 |
Why?
|
Haplotypes | 2 | 2003 | 2715 | 0.020 |
Why?
|
Family Health | 2 | 2002 | 1254 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 822 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2010 | 1867 | 0.020 |
Why?
|
Cell Count | 1 | 2009 | 1831 | 0.010 |
Why?
|
Antigens, Differentiation | 1 | 2007 | 918 | 0.010 |
Why?
|
Developing Countries | 1 | 2016 | 2863 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7033 | 0.010 |
Why?
|
Host vs Graft Reaction | 1 | 2003 | 13 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2008 | 2263 | 0.010 |
Why?
|
Treatment Failure | 1 | 2010 | 2643 | 0.010 |
Why?
|
Skin Diseases | 1 | 2012 | 1095 | 0.010 |
Why?
|
Protozoan Infections | 1 | 2003 | 38 | 0.010 |
Why?
|
Rabbits | 1 | 2010 | 4750 | 0.010 |
Why?
|
Cohort Studies | 4 | 2010 | 41496 | 0.010 |
Why?
|
Receptors, KIR | 1 | 2003 | 110 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6974 | 0.010 |
Why?
|
Doxorubicin | 1 | 2010 | 2224 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1052 | 0.010 |
Why?
|
Haploidy | 1 | 2003 | 126 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2014 | 5478 | 0.010 |
Why?
|
Postoperative Complications | 2 | 2019 | 15637 | 0.010 |
Why?
|
Hematopoiesis | 2 | 2005 | 2049 | 0.010 |
Why?
|
Viral Load | 1 | 2011 | 3328 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1999 | 10218 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4569 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 2002 | 312 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7407 | 0.010 |
Why?
|
Aspergillosis | 1 | 2003 | 242 | 0.010 |
Why?
|
Lymphocyte Depletion | 1 | 2003 | 602 | 0.010 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2003 | 237 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 2001 | 249 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 1989 | 0.010 |
Why?
|
Negotiating | 1 | 2002 | 151 | 0.010 |
Why?
|
Chronic Disease | 1 | 2015 | 9319 | 0.010 |
Why?
|
Graft Enhancement, Immunologic | 1 | 2000 | 58 | 0.010 |
Why?
|
Breast Neoplasms | 2 | 2000 | 20982 | 0.010 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2001 | 326 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2007 | 1613 | 0.010 |
Why?
|
Atovaquone | 1 | 1999 | 56 | 0.010 |
Why?
|
Oxygen | 1 | 2011 | 4228 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2003 | 1351 | 0.010 |
Why?
|
Graft vs Leukemia Effect | 1 | 2000 | 121 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2007 | 1963 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3777 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2009 | 6486 | 0.010 |
Why?
|
Leukemia, Myeloid | 1 | 2002 | 693 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2014 | 14610 | 0.010 |
Why?
|
Chimera | 1 | 1999 | 453 | 0.010 |
Why?
|
Blood Platelets | 1 | 2009 | 2477 | 0.010 |
Why?
|
Neutropenia | 1 | 2003 | 885 | 0.010 |
Why?
|
Prospective Studies | 3 | 2014 | 54437 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 2003 | 1408 | 0.010 |
Why?
|
Cyclosporine | 1 | 2000 | 776 | 0.010 |
Why?
|
Virus Diseases | 1 | 2003 | 716 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2003 | 1348 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4009 | 0.010 |
Why?
|
Stroke Volume | 1 | 2010 | 5521 | 0.010 |
Why?
|
Kinetics | 1 | 2002 | 6312 | 0.010 |
Why?
|
Hospice Care | 1 | 2002 | 678 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5842 | 0.010 |
Why?
|
Animals | 4 | 2010 | 168089 | 0.010 |
Why?
|
Mice | 3 | 2008 | 81330 | 0.010 |
Why?
|
Paclitaxel | 1 | 2001 | 1730 | 0.010 |
Why?
|
Models, Psychological | 1 | 1998 | 830 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2013 | 6506 | 0.010 |
Why?
|
Personal Satisfaction | 1 | 1998 | 645 | 0.010 |
Why?
|
Safety | 1 | 1998 | 1151 | 0.010 |
Why?
|
Models, Animal | 1 | 2000 | 2114 | 0.010 |
Why?
|
United States | 1 | 2021 | 72341 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7400 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1998 | 2928 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2008 | 9417 | 0.010 |
Why?
|
Self Concept | 1 | 1998 | 1046 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 15308 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 2009 | 5114 | 0.010 |
Why?
|
Stem Cells | 1 | 2003 | 3517 | 0.010 |
Why?
|
ROC Curve | 1 | 1998 | 3584 | 0.010 |
Why?
|
Bacterial Infections | 1 | 1998 | 1390 | 0.010 |
Why?
|
Cell Survival | 1 | 2000 | 5778 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2000 | 4909 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2008 | 18222 | 0.000 |
Why?
|
Boston | 1 | 2002 | 9327 | 0.000 |
Why?
|
Regression Analysis | 1 | 1998 | 6345 | 0.000 |
Why?
|
Decision Making | 1 | 2002 | 3931 | 0.000 |
Why?
|
Child, Preschool | 2 | 2002 | 42225 | 0.000 |
Why?
|
Heart Diseases | 1 | 2000 | 2795 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 8002 | 0.000 |
Why?
|
Odds Ratio | 1 | 1998 | 9652 | 0.000 |
Why?
|
Genotype | 1 | 2000 | 12985 | 0.000 |
Why?
|
Multivariate Analysis | 1 | 1998 | 12052 | 0.000 |
Why?
|
Pain | 1 | 1998 | 5072 | 0.000 |
Why?
|
Registries | 1 | 1998 | 8246 | 0.000 |
Why?
|
Child | 2 | 2002 | 80154 | 0.000 |
Why?
|
Phenotype | 1 | 2000 | 16575 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2000 | 20118 | 0.000 |
Why?
|
Neoplasm Staging | 1 | 1995 | 11119 | 0.000 |
Why?
|
Pregnancy | 1 | 2001 | 29893 | 0.000 |
Why?
|